Objective: Patients with contralateral carotid occlusion (CCO) have been excluded from randomized clinical trials because of a deemed high risk for adverse neurologic outcomes with carotid endarterectomy (CEA). Evidence for this rationale is limited and conflicting. Therefore, we aimed to compare outcomes after CEA between patients with and without CCO and varying degrees of contralateral carotid stenosis (CCS).
Several patient-related factors are classified as high-risk, defined by the 14 societies' guideline document, in which both the American Heart Association (AHA) and the Society for Vascular Surgery (SVS) were included, as resulting in an anticipated 30-day stroke or mortality rate >3% for asymptomatic and 6% for symptomatic patients after carotid endarterectomy (CEA), which are also the recommended thresholds used by the European Society for Vascular Surgery.
1,2 These high-risk criteria include severe cardiac or pulmonary disease, contralateral laryngeal nerve palsy, prior neck surgery or irradiation, recurrent stenosis after CEA, age >80 years, and contralateral carotid occlusion (CCO). One of the purposes of these high-risk criteria is to select patients for whom CEA may not be beneficial and for whom carotid artery stenting (CAS) may be the preferred treatment option. However, the criteria and the definition of "high-risk" are both widely debated. 3 CCO is classified as one of the high-risk criteria 1 and used by the Centers for Medicare and Medicaid Services to identify patients for whom CAS will be reimbursed (https://www.cms.gov, CAG-00085R). In addition, CCO has been applied as an exclusion criterion in clinical trials because of its deemed increased surgical stroke risk. 4, 5 Evidence to support this hypothesis is conflicting, however. Although the North American Symptomatic Carotid Endarterectomy Trial (NASCET) demonstrated a high stroke/death rate of 14.3% in patients with CCO, 6 others found no difference or a marginally higher risk in patients with CCO compared with patients without CCO. 7, 8 In addition, studies focusing on contralateral carotid stenosis (CCS) are scarce but show similar conflicting results. 6, 9, 10 Evidence concerning the underlying pathophysiological mechanism of the higher stroke risk associated with CCO is scarce. In theory, impaired intraoperative cerebral perfusion, caused by an insufficient collateral circulation at cross-clamping, along with the risk for postoperative cerebral hyperperfusion, could lead to perioperative strokes in patients with CCO. We used the Vascular Study Group of New England (VSGNE) registry, a large regional registry reflecting realworld vascular surgery practice (ie, including academic and community centers), to test our hypothesis that neither CCO nor CCS would result in a 30-day stroke/ death rate after CEA of >3% in asymptomatic patients or >6% in symptomatic patients.
METHODS
The Beth Israel Deaconess Medical Center Institutional Review Board approved this project and waived the need for informed consent for the use of deidentified data in the VSGNE. VSGNE Registry. We used the VSGNE registry for this analysis. The VSGNE is a prospective regional clinical registry comprising 14 academic and 16 community hospitals in the states of Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont. The goal of the VSGNE is to improve quality, safety, and effectiveness of vascular health care by monitoring >200 predefined variables on patient demographics, operative details, and clinical outcomes. 11, 12 All data in the VSGNE are entered by surgeons and trained nurses or clinical data abstractors, making it distinct from administrative data sets. Operative details are entered by the treating surgeons. Research analysts are blinded to patient, surgeon, and hospital identity. Annual audits of discharge claims are performed for each participating hospital to ensure consecutive procedure entry of appropriate cases and to eliminate inconsistencies between claims data and procedures entered into VSGNE, with the goal to eliminate selection bias by ensuring that each physician entered 100% of the eligible procedures. VSGNE also retrieves mortality data from the Social Security Death Index, which is compared with mortality data recorded by centers included in the VSGNE. 13 Additional information on this regional registry is available at http://www.vascularqualityinitiative.org/ components-of-the-vqi/regional-quality-groups/currentregional-quality-groups/vascular-study-group-of-newengland/.
Patient cohort. Our initial study sample included all patients (n ¼ 17,001) in the VSGNE who underwent CEA End points and measurements. The main exposure variable was the presence of CCO, and to a lesser extent, the degree of stenosis of the contralateral ICA, subdivided into <50%, 50% to 80%, and 80% to 99%. The degree of stenosis was diagnosed by one or more of the following imaging modalities at admission: duplex ultrasound imaging, computed tomography angiography, magnetic resonance angiography, or arteriogram, at the discretion of the treating physician. Symptomatic patients in this registry were defined as having an ipsilateral neurologic event, including any hemispheric or ocular transient ischemic attack, or minor or major stroke preceding the intervention. 13, 14 Our primary end point was risk of any stroke or death #30 days, hereafter referred to as 30-day stroke/ death. Secondary end points were 30-day mortality, any in-hospital stroke, in-hospital ipsilateral stroke, in-hospital contralateral stroke, and prolonged length of stay (LOS).
Besides mortality and any stroke at 30 days, all reported outcomes were in-hospital events during the index admission as a result of limitations of the VSGNE registry. All mortality data were supplemented with data from the Social Security Death Index, allowing us to analyze 30-day death rates reliably.
Strokes that occurred after discharge were recorded at subsequent follow-up visits, which took place at any time after the operation. motor or sensory loss, speech abnormality, or any other neurologic symptoms related to the right or left hemisphere, lasting at least 24 hours), used by the registry included major (any cortical, vertebrobasilar, or ocular disability resulting in dependent living status, or blindness) and minor strokes (all remaining strokes).
Prolonged LOS was defined as discharge after the second postoperative day or any discharge to a skilled nursing facility for patients who were admitted from home for the index operation, as defined by the Medicare Physician Quality Reporting System, measure 260 (http://www.cms.gov).
Patients were stratified by preoperative symptom status and compared by presence of CCO. This resulted in four initial patient groups: symptomatic patients (1) with and (2) without CCO and asymptomatic patients (3) with and (4) without CCO.
In addition, we compared patients by degree of CCS, including CCO, resulting in eight CCS groups: symptomatic patients with CCS of (1) <50%, (2) 50% to 80%, (3) 80% to 99%, or (4) CCO, and asymptomatic patients with CCS of (5) <50%, (6) 50% to 80%, (7) 80% to 99%, or (8) CCO.
Statistical analysis. Categoric variables are presented as counts and percentages and continuous variables as mean 6 standard deviation or median and interquartile range (IQR), where appropriate. To assess differences between groups in our univariate analysis, we used c 2 and
Fisher exact tests for categoric variables and the Student t-test and Mann-Whitney U test for continuous variables, where appropriate. We performed multivariable logistic regression to test the independent association between CCO and our primary and secondary outcomes. 15, 16 In addition, we tested the association between the degree of CCS and our primary and secondary outcomes, using <50% CCS as the referent. To reach an adequate number of adverse events for multivariable analysis, symptomatic and asymptomatic patients were combined and adjusted for in all multivariable models. We identified variables for inclusion in our models using purposeful selection, which combines previously identified risk factors with confounders and significant covariates. 15 We used the Hosmer-Lemeshow test for the evaluation of model stability. Associations with a P value of <.05 were considered significant. SPSS 22.0 software (IBM, Armonk, NY) was used for statistical analyses.
RESULTS
Of 15,487 patients, 60% were male, mean age was 70 6 9.3, and 5110 (33%) were symptomatic. Of the symptomatic patients, 233 (4.6%) had CCO and 333 (6.5%) had 80% to 99% CCS. Of the 10,377 asymptomatic patients, 681 (6.6%) had CCO and 705 (6.8%) had 80% to 99% CCS. Table I reports the baseline patient characteristics and operative details, stratified by symptom status and presence of CCO. Symptomatic and asymptomatic patients with CCO, compared with those with a patent contralateral ICA, were younger, less often women, more often had a prior ipsilateral CEA, and were more likely to receive an intraluminal shunt during the procedure. Among symptomatic patients, preoperative renal insufficiency (defined by the VSGNE registry as a preoperative creatinine $1.78 mg/dL) was more common in patients with CCO than in those without. For asymptomatic patients, dual-antiplatelet therapy on admission (aspirin and P2Y 12 -inhibitor) and prior neck radiotherapy were more common in patients with CCO, than in patients with a patent contralateral ICA. Supplementary Table I (online only) summarizes baseline patient characteristics and operative details of the CCS groups, stratified by symptom status.
Patient characteristics

Univariate analysis
Symptomatic patients. On univariate analysis, 30-day stroke/death (2.6% vs 2.0%; P ¼ .6), 30-day mortality (0.4% vs 0.8%; P ¼ 1.0), any in-hospital stroke (2.1% vs 1.3%; P ¼ .2), in-hospital ipsilateral stroke (1.7% vs 1.1%; P ¼ .3), and in-hospital contralateral stroke (0.9% vs 0.2%; P ¼ .1) were comparable between symptomatic patients with CCO and without CCO (Table II) . Prolonged LOS was more likely in patients with CCO than in those with a patent contralateral ICA (22% vs 17%; P ¼ .03).
Asymptomatic patients. Compared with asymptomatic patients with a patent contralateral ICA, asymptomatic patients with CCO had a higher rate of 30-day stroke/ death (2.3% vs 1.0%; P ¼ .003), any in-hospital stroke (2.1% vs 0.6%; P < .001), in-hospital ipsilateral stroke (1.2% vs 0.5%; P ¼ .03), in-hospital contralateral stroke (0.9% vs 0.2%; P ¼ .002), and prolonged LOS (15% vs 9.8%; P < .001) (Table II) . Mortality at 30 days was comparable between asymptomatic patients with CCO and without CCO (0.6% vs 0.4%; P ¼ .5).
Symptomatic and asymptomatic patients with CCS. Supplementary Table II (online only) summarizes the univariate analysis of outcomes for the CCS groups. Notably, in-hospital contralateral stroke rates differed between CCS groups, for both symptomatic (<50% CCS: 0.1%; 50%-79% CCS: 0.3%; 80-99% CCS: 0.6%; CCO: 0.9%; P ¼ .04) and asymptomatic patients (50% CCS: 0.1%; 50%-79% CCS: 0.2%; 80%-99% CCS: 0.1%; CCO: 0.9%; P ¼ .01).
Multivariable analysis
Comparison on presence of CCO. associations of included covariates in our multivariable model on the outcome of 30-day stroke/death.
Comparison on degree of CCS. The Fig illustrates the associations between the CCS groups and our primary and secondary outcomes in our multivariable model, with <50% CCS set as referent. After adjustment, CCO was independently associated with a higher risk of 30-day stroke/death (OR, 2.2; 95% CI, 1.4-3.6; P ¼ .001), any in-hospital stroke (OR, 2.9; 95% CI, 1.7-4.9; P < .001), in-hospital ipsilateral stroke (OR, 2.1; 95% CI, 1.1-4.0; P ¼ .02), in-hospital contralateral stroke (OR, 7.1; 95% CI, 2.8-17.9; P < .001), and prolonged LOS (OR, 1.7; 95% CI, 1.4-2.0; P < .001). CCS, either 50% to 79% or 80% to 99%, was not associated with 30-day stroke/death or inhospital stroke, but 80% to 99% CCS was associated with prolonged LOS (OR, 1.3; 95% CI, 1.1-1.6; P ¼ .01). Mortality at 30 days was not associated with CCO, 50% to 79% CCS, or 80% to 99% CCS. Supplementary Table III (online only) summarizes the associations of included covariates in our multivariable model on the outcome of 30-day stroke/death.
DISCUSSION
In a large clinical registry, we found that CCO was adversely associated with 30-day stroke/death, any in-hospital stroke, in-hospital ipsilateral and contralateral stroke, and prolonged LOS but not with 30-day mortality. Neither 50% to 80% CCS nor 80% to 99% CCS was associated with 30-day stroke/death, 30-day mortality, or in-hospital stroke.
Although CCO resulted in a slightly higher stroke/death risk after CEA, more importantly, CCO did not meet the criteria set by the 14 societies' guideline document to classify as a "high-risk" criteria, because 30-day stroke/ death rates in both symptomatic and asymptomatic patients remained well within the guidelines. On the one hand, it seems counterintuitive to consider patients with CCO as unsuitable for surgical intervention, especially because we should take into account that some of the observed perioperative strokes are not directly related to the procedure but to the inherent stroke risk of carotid disease. On the other hand, there is no evidence that stroke risk related to stenting in patients with CCO is lower than that in surgery.
The overall proportion of patients with CCO (5.9%) and CCS 80% to 99% (6.7%), as identified by the VSGNE registry, were comparable to prior reports. 9,10,17 However, our reported overall 30-day stroke/death rate of 2.4% in patients with CCO was low compared with previously reported rates, that ranged from 0.7% to 16%. 6, 18, 19 This may be partly a result of the decline of stroke/death rates for all CEA patients over time 19 or because postdischarge strokes in our regional registry were underestimated. Although several prior studies used the VSGNE registry to report 30-day stroke/death rates after CEA, [20] [21] [22] the coding of postdischarge strokes and their timing in VSGNE precludes determination of the proportion of patients with complete follow-up up to 30 days after surgery. However, 1-year follow-up was complete for 77% of all CEA patients. Postdischarge strokes accounted for 14% of all strokes in our sample, whereas postdischarge strokes in a prior study accounted for almost one-third. 23 However, even if we were to apply the latter postdischarge stroke percentage, that is, assuming that one of three strokes occurred after discharge, instead of our observed one of seven, our 30-day stroke/death rate would still be below the guideline thresholds, with an estimated 30-day stroke/death rate of 3.4% for symptomatic and 2.6% for asymptomatic patients. The effect of CCS or CCO on outcomes after CEA has been disputed. Some studies found no increased risk of 30-day stroke or death in patients with CCO, 24, 25 whereas others reported an increased 30-day stroke risk for patients with CCO but no increased risk for 30-day mortality. 17, 26 These differences are likely related to the small sample of patients with CCO in most studies. 18, 19 Our prior study, using the SVS Vascular Registry, included 274 patients with CCO undergoing CEA. We identified CCO as an independent predictor of 30-day stroke/death and reported a 30-day stroke/death rate of 16.1% for symptomatic and 7.2% for asymptomatic patients. 27 However, Ricotta et al, 17 in a subsequent analysis using the SVS Vascular Registry with a larger number of CCO patients, reported a much lower event rate in CCO patients (30-day mortality of 0.7% and 30-day stroke of 3.1%), which is more in line with our reported event rates for patients with CCO. Thus, the disparity in event rates after CEA between our prior and current study is likely related to the small number of CCO patients in our prior analysis. In addition, a decline of adverse events after surgery over time, combined with better medical management, might explain the improved outcomes after CEA in our current analysis.
However, when we compared crude 30-day stroke/death rates per year for patients with CCO, we did not identify a trend, likely a result of the relatively small annual number patients with CCO. Moreover, we found significantly worse outcomes for CAS in our prior study compared with CEA, after adjusting for several high-risk criteria, including CCO. 27 A recent systematic review comparing perioperative outcomes after CAS vs CEA in a population at average risk also found significantly worse outcomes for CAS compared with CEA, which even exceed the 14 societies' guideline thresholds. 28 With regard to the higher incidence of prolonged LOS in patients with CCO, we hypothesize that it resulted not only from their slightly higher stroke/death rate but also from their higher burden of comorbidities. One study reported worse outcomes for patients with CCS after CEA compared with CCO; however, the CCS patients received bilateral CEA, and all strokes in this group occurred after the second intervention. 9 Two other studies identified CCS as a predictor of 30-day stroke/ death after CEA. 10, 29 However, neither compared outcomes between patients with CCS and CCO directly, impeding the comparison to our results. Our observed association between in-hospital contralateral stroke and CCO is difficult to put into perspective because most studies report an overall stroke rate or an ipsilateral stroke rate. However, we hypothesize that contralateral strokes in patients with CCO are related to an insufficient collateral circulation at cross-clamping, causing strokes to occur in a watershed area, potentially triggered by inadequate anterior or posterior ; (D) in-hospital ipsilateral stroke 1 ; (E) in-hospital contralateral stroke 1 ; and (F) prolonged length of stay (LOS). 1 Adjusted for age, gender, symptom status, preoperative renal insufficiency, preoperative dual antiplatelet usage, degree of ipsilateral carotid stenosis (ie, <80%, $80%), and urgency. CCS <50% is referent in each multivariable model. *P < .05. CCO, Contralateral carotid occlusion; CI, confidence interval; OR, odds ratio.
communicating arteries in the circle of Willis. 30 However, in patients with CCO, regardless of symptom status, comparing patients who did and did not receive a shunt, we found no protective effect of shunting for in-hospital strokes nor did we find a difference between patients with and without CCO in the rates of hyperperfusion, with 0% vs 0.1% in symptomatic and 0.2% vs 0.1% in asymptomatic patients, likely due to the overall low incidence of 0.17%. The results of this study must be interpreted within the context of its design. Several limitations are inherent to our regional registry. First, the predefined variables captured by the registry preclude additional detailed analysis based on the characteristics and mechanism of each reported stroke as well as the timing of preprocedural neurologic symptoms because these data are not captured.
Second, we performed a retrospective analysis of the prospectively collected data in our regional registry; this design does not obviate bias as a randomized trial would. However, we were able to partly account for this by our large sample size, which allowed for adjusted analysis.
Third, we were not able to compare symptomatic vs asymptomatic patients directly owing to the low adverse event rates. However, we identified a similar effect size and direction in asymptomatic and symptomatic patients for our outcomes, which allowed us to merge these patients and adjust for symptom status in our models.
Despite these limitations, our regional registry did provide one of the largest samples of patients with CCO in a real-world setting, allowing adjusted analysis. This was not possible previously because of low rates of stroke and death after CEA. 18, 19 
CONCLUSIONS
Although CCO increased the risk of 30-day stroke/death and in-hospital strokes, CCO did not meet the criteria set by the 14 societies' guideline document to classify as "high-risk," because as stroke/death rates in both symptomatic and asymptomatic patients remained well within the guidelines. Moreover, there is no evidence that patients with CCO have lower stroke/death rates after CAS than after CEA, and even the opposite is suggested by registry studies. We believe that CEA remains a valid and safe option for patients with CCO and that CCO should not be applied as criterion to promote carotid stenting per se. 
